CurrentCignaPolicy N/A

Imcivree (setmelanotide) prior authorization for genetic and syndromic obesity

Defines Cigna's prior authorization criteria, coverage stance, and duration for Imcivree for patients ≥2 years with POMC, PCSK1, or LEPR deficiency or Bardet-Biedl syndrome; applies to Cigna-administered health benefit plans.

Policy Summary

PayerCigna

PolicyImcivree (setmelanotide) prior authorization for genetic and syndromic obesity

Policy CodePolicy N/A

Change TypeAge criterion and terminology revisions

Effective DateN/A

Next Review DateJan 14, 2026

Key ActionObtain prior authorization and document genetic testing demonstrating homozygous or compound heterozygous variants (or clinical diagnosis for Bardet‑Biedl) and specialist involvement.

SourceLink

POLICY UPDATE CHANGES

Age criterion updated to ≥ 2 years (previously ≥ 6 years) for initial therapy and continuing therapy for POMC/PCSK1/LEPR deficiency and Bardet-Biedl syndrome.

Terminology changed from 'mutations' to 'variants' for genetic testing requirement (homozygous or compound heterozygous).

≥2 yrsMin eligible age

4 moInitial approval (POMC/PCSK1/LEPR)

1 yrApproval duration (responders/BBS)

≥5%Responder threshold

Trek Health ingests and normalizes Transparency in Coverage data and payer policy updates to give provider organizations a clear view of how commercial reimbursement behaves across markets, payers, and services. Our platform transforms raw payer disclosures into structured intelligence that supports contract evaluation, payer negotiations, and service line strategy. By combining market benchmarks with ongoing policy visibility, Trek helps teams identify variability, risk, and opportunity in commercial reimbursement. The result is faster insight, stronger negotiating positions, and more informed financial decisions.

Coverage Criteria for Imcivree (setmelanotide)

Initial Therapy (POMC/PCSK1/LEPR)

Covered for Obesity Due to POMC, PCSK1, or LEPR Deficiency when meeting ALL of the following for Initial Therapy:

Initial Therapy for POMC/PCSK1/LEPR deficiency: i. Patient is ≥ 2 years of age; AND ii. Genetic testing demonstrates homozygous or compound heterozygous variants in POMC, PCSK1, or LEPR AND the genetic variant is interpreted as pathogenic, likely pathogenic, or of uncertain significance; AND iii. Patient meets ONE of: (a) ≥18 years with BMI ≥30 kg/m2; OR (b) 6–17 years with weight ≥95th percentile for age; OR (c) 2 to ≤5 years with weight ≥97th percentile for age; AND iv. Medication is prescribed by or in consultation with an endocrinologist, a geneticist, or a physician who specializes in metabolic disorders.N/A

Initial approval: 4 months

Continuation Therapy (POMC/PCSK1/LEPR)

Continuation Therapy for POMC/PCSK1/LEPR Deficiency (Patient Currently Receiving Imcivree):

Continuation Therapy for POMC/PCSK1/LEPR deficiency: i. Patient is ≥ 2 years of age; AND ii. Genetic testing demonstrates homozygous or compound heterozygous variants in POMC, PCSK1, or LEPR AND the genetic variant is interpreted as pathogenic, likely pathogenic, or of uncertain significance; AND iii. Patient meets ONE of: (a) Patient has lost ≥5% of baseline body weight since initiating Imcivree; OR (b) Patient has continued growth potential AND has lost ≥5% of baseline BMI since initiating Imcivree; AND iv. Medication is prescribed by or in consultation with an endocrinologist, a geneticist, or a physician who specializes in metabolic disorders.Responder = ≥5% weight or BMI reduction

Approval duration: 1 year

Initial Therapy (Bardet-Biedl Syndrome)

Covered for Obesity Due to Bardet-Biedl Syndrome when meeting ALL of the following for Initial Therapy:

Initial Therapy for Bardet-Biedl Syndrome: i. Patient is ≥ 2 years of age; AND ii. Clinical diagnosis of Bardet-Biedl syndrome defined by either (a) at least FOUR primary features (rod-cone dystrophy, polydactyly, obesity, learning disability, renal anomalies, male hypogonadism); OR (b) at least THREE primary features plus at least TWO secondary features (speech disorder/delay, developmental delay, polyuria/polydipsia/nephrogenic diabetes insipidus, dental anomalies, ataxia/poor coordination, mild spasticity, arched palate, cardiac anomalies, hepatic fibrosis); AND iii. Patient meets ONE of: (a) ≥18 years with BMI ≥30 kg/m2; OR (b) <18 years with weight ≥97th percentile for age; AND iv. Medication is prescribed by or in consultation with an endocrinologist, a geneticist, or a physician who specializes in metabolic disorders.N/A

Approval duration: 1 year

Continuation Therapy (Bardet-Biedl)

Continuation Therapy for Bardet-Biedl Syndrome (Patient Currently Receiving Imcivree):

Continuation Therapy for Bardet-Biedl Syndrome: i. Patient is ≥ 2 years of age; AND ii. Patient has lost ≥5% of baseline body weight since initiating Imcivree OR (for patients <18 years) has lost ≥5% of baseline BMI since initiating Imcivree; AND iii. Medication is prescribed by or in consultation with an endocrinologist, a geneticist, or a physician who specializes in metabolic disorders.Responder = ≥5% weight or BMI reduction

Approval duration: 1 year

Use of Imcivree for genetic obesity syndromes other than those specifically listed in this policy is considered not medically necessary. Examples called out in the source include syndromes such as Prader‑Willi and Alström. Clinical trial data cited for Alström syndrome did not demonstrate the prespecified primary efficacy endpoint in the small sample evaluated.

Imcivree is not indicated for genetic obesity syndromes other than POMC-, PCSK1-, or LEPR-deficient obesity or Bardet‑Biedl syndrome, and it is not indicated for general (polygenic) obesity.

Coding and Response Thresholds

Covered CPT Codesmixed

No codes listed

Not covered (indications)neutralNot Covered

No codes listed

inv-09: Weight/BMI response threshold

Response threshold for continuing coverage≥ 5% reduction from baseline body weight OR ≥ 5% reduction from baseline BMI for patients with continued growth potential

Measurement timingCalculated since initiating Imcivree therapy at the time of continuation review

Minimum responder definition applies toPatients with POMC, PCSK1, or LEPR deficiency and patients with Bardet‑Biedl syndrome during continuation reviews

Approval duration tied to responseResponders approved for 1 year (after initial approval period) per policy

inv-10: Age and obesity definitions

Adult obesity definition (≥18 years)

Provider Actions, Authorization, and Documentation

Prior Authorization

Prior Authorization Recommended

Prior Authorization is recommended for prescription benefit coverage of Imcivree. All approvals are time-limited; when authorized in months, 1 month = 30 days. Because of required specialized evaluation and monitoring, Imcivree must be prescribed by or in consultation with a physician who specializes in the condition being treated (e.g., endocrinologist, geneticist, or metabolic disorders specialist).

Prior authorization recommended for Imcivree (setmelanotide).
Approvals are time-limited; months = 30 days.
Prescriber requirement: prescribed by or in consultation with a specialist in the treated condition (endocrinologist, geneticist, or metabolic disorders specialist).

Step Therapy

Step Therapy / Sequencing

There is no formal step therapy sequence required. However, continuation of therapy and authorization decisions are governed by specialist-prescribing and response criteria (initial therapy vs continuation therapy), including time-limited approvals (e.g., initial approval period vs continuation approval periods) and documented clinical response.

Background

Genetic forms of severe early‑onset obesity arise from defects in components of the leptin‑melanocortin pathway; disorders such as POMC, PCSK1, and LEPR deficiency disrupt signaling that regulates appetite and energy balance. Imcivree (setmelanotide) acts as a melanocortin‑4 receptor agonist to address this pathway dysfunction in patients with qualifying monogenic causes or in patients with Bardet‑Biedl syndrome. The policy limits use to the specified genetic diagnoses because available clinical evidence does not support benefit of Imcivree for other genetic obesity syndromes or for general obesity (for example, a small Phase III subgroup with Alström syndrome did not meet the primary weight‑loss endpoint).

Definitions

inv-16: Response to therapy

Responder definition for continuation therapyPatient has lost ≥ 5% of baseline body weight since initiating Imcivree; OR for patients with continued growth potential, has lost ≥ 5% of baseline BMI since initiating Imcivree

Documentation required to demonstrate responseRecorded baseline weight/BMI and subsequent weight/BMI measurements showing ≥5% reduction

Timing considerationIf patient has not completed at least initial therapy period, refer to initial therapy criteria (initial approval: 4 months for monogenic indications)

inv-17: Genetic confirmation

Required genetic zygosityHomozygous or compound heterozygous variants in POMC, PCSK1, or LEPR

Variant interpretationVariant must be interpreted as pathogenic, likely pathogenic, or of uncertain significance